Guo J - Search Results

1

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Motzer RJ, et al. Among authors: guo j. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. N Engl J Med. 2013. PMID: 23964934 Free article. Clinical Trial.

2

[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma].

Si L, Bai X, Mao L, Wang X, Chi Z, Cui C, Sheng X, Tang B, Guo J. Si L, et al. Among authors: guo j. Zhonghua Yi Xue Za Zhi. 2014 Sep 9;94(33):2580-3. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25511488 Chinese.

3

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.

Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D. Qin S, et al. Among authors: guo j. Onco Targets Ther. 2015 Jun 8;8:1363-73. doi: 10.2147/OTT.S83302. eCollection 2015. Onco Targets Ther. 2015. PMID: 26089686 Free PMC article.

4

[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].

Cui C, Li S, Chi Z, Si L, Sheng X, Mao L, Lian B, Wang X, Tang B, Guo J. Cui C, et al. Among authors: guo j. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):375-8. Zhonghua Zhong Liu Za Zhi. 2015. PMID: 26463030 Chinese.

5

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Sheng X, et al. Among authors: guo j. Oncotarget. 2016 May 10;7(19):27044-54. doi: 10.18632/oncotarget.7395. Oncotarget. 2016. PMID: 26894858 Free PMC article.

6

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.

Zhang HL, Sheng XN, Li XS, Wang HK, Chi ZH, He ZS, Ye DW, Guo J. Zhang HL, et al. Among authors: guo j. BMC Cancer. 2017 Jan 5;17(1):16. doi: 10.1186/s12885-016-3016-4. BMC Cancer. 2017. PMID: 28056874 Free PMC article.

7

Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma.

Qin SK, Jin J, Guo J, Wang JW, Zhou FJ, Huang YR, Ren XB, Ye DW, Pan S, Sajben P, Wang Q. Qin SK, et al. Among authors: guo j. Future Oncol. 2018 Aug;14(18):1835-1845. doi: 10.2217/fon-2017-0733. Epub 2018 May 2. Future Oncol. 2018. PMID: 29717651 Clinical Trial.

8

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R. Guo J, et al. J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1. J Hematol Oncol. 2018. PMID: 29788981 Free PMC article. Clinical Trial.

9

Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.

Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S, Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J. Sheng X, et al. Among authors: guo j. Eur J Cancer. 2018 Sep;100:1-7. doi: 10.1016/j.ejca.2018.04.007. Epub 2018 Jun 19. Eur J Cancer. 2018. PMID: 29933095 Clinical Trial.

10

First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.

Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J. Sheng X, et al. Among authors: guo j. Future Oncol. 2019 Jan;15(1):53-63. doi: 10.2217/fon-2018-0442. Epub 2018 Jul 30. Future Oncol. 2019. PMID: 30058839 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32,171 results

Search Page

Filters